The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC).
 
Yasir Elamin
No Relationships to Disclose
 
Daniel Richard Gomez
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Merck
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Hai T. Tran
No Relationships to Disclose
 
Waree Rinsurongkawong
No Relationships to Disclose
 
Jeff Lewis
No Relationships to Disclose
 
Lara Lacerda
No Relationships to Disclose
 
Emily Roarty
No Relationships to Disclose
 
J. Jack Lee
No Relationships to Disclose
 
Jack A. Roth
No Relationships to Disclose
 
Stephen Swisher
No Relationships to Disclose
 
Jianjun Zhang
No Relationships to Disclose
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)